key: cord-0940155-ik0qneuj authors: Fishman, Jay A.; Alter, Galit title: Humoral immune responses against SARS‐CoV‐2 in transplantation: Actionable biomarker or misplaced trust? date: 2022-03-10 journal: Am J Transplant DOI: 10.1111/ajt.17018 sha: 3f7cd5e6e9655e7f034f25879001d53cdefd9a05 doc_id: 940155 cord_uid: ik0qneuj Measures of vaccine‐specific antibodies to SARS‐CoV‐2, as discussed by Werbel and Segev (Page 1316), may ignore responses to contemporaneous variants of concern and relevant cellular immune responses, thereby failing to provide the insights required to optimize clinical care. In addition to a remarkable ability to spread and mutate, severe acute Boosting improves antibody quality in immune competent hosts via enhanced affinity maturation, providing antibodies that recognize a broader array of variants. 14 In immunocompromised hosts, incomplete responses to vaccination could produce greater humoral immune responses in the absence of enhanced affinity maturation. Such lower affinity antibodies may neutralize wildtype SARS-CoV-2 found in vaccines, but with lesser cross-reactivity to additional variants of concern (e.g., Omicron). Incomplete affinity maturation in SOT could relate to impaired T cell help, disrupted germinal center activity, or altered antigen presentation. 15 Thus, in the absence of a complete understanding the affin- Clinical laboratories are overwhelmed with requests for diagnostic assays during COVID. In a viewpoint paper by Werbel and Segev, measurement of antibody levels is advocated as an adjunct to clinical management. 16 They recommend quantitative FDA emergency use authorized anti-S1/RBD assays after full vaccination to assess antibody responses. As they note, there are few data supporting Mab use in vaccinated seronegative SOT recipients (or poor responders). The key question is whether antibody levels in SOT recipients are actionable biomarkers or simply an available assay, reassuring to the physician or patient but failing to reflect immune function? AJT EDITORIAL With the appearance of Omicron BA.2, emerging antiviral therapies must be provided to those least likely to mount an effective immune response. Based on which tests? And is this the best use of a limited resource? In the immunodominant spike (S) protein, 5106 different amino acid replacements or substitutions have been identified as well as multiple deletions. 17 As variants emerged, natural antibodies (from prior infection), therapeutic monoclonal antibodies (targeting prior strains), and some vaccine-elicited antibodies have become less effective in preventing disease progression. 18 More than 85% of tested neutralizing antibodies are escaped by Omicron 19 ; nearly all are escaped by Omicron sublineage BA.2. 20 Thus, routine assays for SARS-CoV-2 antibody levels might erroneously suggest viral protection when none exists to emerging variants. Antibody levels provide an imperfect foundation for decisions regarding disease prevention or treatment. Assays of neutralizing antibodies detect vaccine-specific antibodies but may not measure antibodies to contemporaneous variants of concern. Furthermore, maintenance of antibody levels sufficient to maintain lifelong protection against viral transmission is an unrealistic goal. Instead, we need to understand the precise functional correlates of immunity responsible for disease control. Emerging multiplexed antibody assays will interrogate antibody binding across variants and may provide information regarding the efficacy of vaccine-induced or monoclonal transmission blocking activity. As further vaccine variants emerge, new pan-variant vaccines will be required. Identification of the key correlates of immunity will provide SOT patients and clinicians the insights required to optimize clinical care in this and future pandemics. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation. antibody biology, editorial/personal viewpoint, immune regulation, immunosuppression/immune modulation, infection and infectious agents-viral: SARS-CoV-2/COVID-19, infectious disease, vaccine Jay A. Fishman 1 SARS-CoV-2-specific T cells in infection and vaccination Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: interim results from a prospective observational cohort study Impaired humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech) Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients Antibody kinetics and durability in SARS-CoV-2 mRNA vaccinated solid organ transplant recipients Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients COVID-19 and X-linked agammaglobulinemia (XLA) -insights from a monogenic antibody deficiency Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients Discordance between SARS-CoV-2-specific cell-mediated and antibody responses elicited by mRNA-1273 vaccine in kidney and liver transplant recipients Correlates of protection against SARS-CoV-2 in rhesus macaques Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts Pre-existing polymerasespecific T cells expand in abortive seronegative SARS-CoV-2 mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant The role of systems vaccinology in understanding the immune defects to vaccination in solid organ transplant recipients SARS-CoV-2 antibody testing for transplant recipients: a tool to personalize protection versus COVID-19 SARS-CoV-2 variants, spike mutations and immune escape SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies Antibody evasion properties of SARS-CoV-2 Omicron sublineages